Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Biotech Business Models From 1999

This article was originally published in Start Up

Executive Summary

Advice of Counsel predicts the seven new business models that are likely to predominate in the months ahead, including "made to order" service deals; second-generation database companies; technology transfer from biotechs to big pharma; building a company to sell; holding onto a share of the upside of a late-stage product; skipping the high-risk phases of drug development; and diversifying the risk-reward tradeoff.


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts